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Model of fibrolamellar hepatocellular carcinomas
reveals striking enrichment in cancer stem cells
Tsunekazu Oikawa1,2,3,*, Eliane Wauthier1,2,3,*, Timothy A. Dinh4,5,6, Sara R. Selitsky4,7, Andrea Reyna-Neyra8,
Guido Carpino9, Ronald Levine10,11, Vincenzo Cardinale12, David Klimstra13, Eugenio Gaudio14, Domenico
Alvaro12, Nancy Carrasco8, Praveen Sethupathy3,4,5,7,** & Lola M. Reid1,2,3,**
The aetiology of human fibrolamellar hepatocellular carcinomas (hFL-HCCs), cancers
occurring increasingly in children to young adults, is poorly understood. We present
a transplantable tumour line, maintained in immune-compromised mice, and validate it as a
bona fide model of hFL-HCCs by multiple methods. RNA-seq analysis confirms the presence
of a fusion transcript (DNAJB1-PRKACA) characteristic of hFL-HCC tumours. The hFL-HCC
tumour line is highly enriched for cancer stem cells as indicated by limited dilution
tumourigenicity assays, spheroid formation and flow cytometry. Immunohistochemistry on
the hFL-HCC model, with parallel studies on 27 primary hFL-HCC tumours, provides robust
evidence for expression of endodermal stem cell traits. Transcriptomic analyses of the tumour
line and of multiple, normal hepatic lineage stages reveal a gene signature for hFL-HCCs
closely resembling that of biliary tree stem cells—newly discovered precursors for liver and
pancreas. This model offers unprecedented opportunities to investigate mechanisms
underlying hFL-HCCs pathogenesis and potential therapies.
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H
uman fibrolamellar hepatocellular carcinomas (hFL-
HCCs) are unique in that they occur primarily in
children to young adults without evidence of fibrosis or
cirrhosis1–5. The epidemiological factors are unknown, as are
causes of increases in occurrence in hFL-HCCs over the pastB60
years6. These malignances are treatable only by surgery and
only if diagnosed before the occurrence of metastases. All
forms of chemo and external radiation therapy have proven
ineffective. Molecular mechanisms and screens for novel
therapies have been difficult to study, since only fresh tissue or
paraffin sections have been available, and those are in limited
supply. There are no cell lines, and until our studies, no
transplantable tumour lines of hFL-HCCs.
We established the first-ever hFL-HCC transplantable tumour
line in immune-compromised murine hosts and compared its
phenotypic features with those of 27 primary hFL-HCC tumours.
The hFL-HCC tumour line proved rich in cancer stem cells
(CSCs). The hFL-HCCs were found to be most closely related to
normal human biliary tree stem cells (hBTSCs), newly discovered
stem cell subpopulations found throughout the biliary tree and
now shown to be precursors to both liver and pancreas7–14.
Results
Establishment of a patient-derived xenograft hFL-HCC model.
A young male patient was diagnosed with hFL-HCC and was
subjected to liver surgery and chemotherapies, all proving
unsuccessful. A more detailed presentation of the diagnosis of the
tumour and its progression is given in the Supplementary Note 1
and Supplementary Table 1. Within 2 years, the tumour had
metastasized and generated ascites tumour cells. Approximately 5
liters of ascites fluid were removed from the patient. Cells from 4
of the liters were delivered to the Reid lab at University of North
Carolina (UNC) and were cultured in Kubota’s Medium (KM), a
serum-free medium found effective for culture selection of
endodermal stem/progenitors7,11,15,16. Culture-selected cells
(2 107 cells) were transplanted into NOD SCID gamma
(NSG) immune-compromised mice. The initial tumour
formation in the mice required 46 months (Table 1).
Transplantation of the tumour line stabilized by supplements.
Tumours were transplanted every 3–5 months. Successful serial
transplantation (from mouse to mouse) was stabilized at B3
months/passage with transplantation of B106 cells in KM
supplemented with 1mgml 1 hyaluronans and with 50 ngml 1
each of hepatocyte growth factor (HGF) and vascular endothelial
cell growth factor (VEGF; Fig. 1a and Table 1). The trans-
plantable, subcutaneous tumours were aggressive in being able to
penetrate through the body wall into the peritoneum. They were
nodular and difficult to mince. If transplanted intraperitoneally
(Fig. 1b), ascites tumours formed afterB8 weeks and gave rise to
nodules on all serosal surfaces within the abdomen.
Histology of the tumour line matched that of original tumour.
The histology of the original tumour (Fig. 1c) and of the original
ascites tumour cells (Supplementary Fig. 1) versus that of
xenografts (Fig. 1d) revealed distinctions between tumour centres
and perimeters, sites at which tumours interfaced with host
tissues. Tumour centres demonstrated histology similar to that
of the original tumour with large polygonal cells, abundant
eosinophilic cytoplasm, large, vesiculated nuclei and large
nucleoli. By contrast, histology at tumour perimeters comprised
incomplete ductular structures with partially stabilized lumens
and with features similar to that of intrahepatic, mixed-type
cholangiocarcinomas (CCAs) with ductular areas17.
Host mesenchymal cells depleted from xenografts by sorting.
Mesenchymal cells within xenografted tumours comprised
B55–70% of cell suspensions from subcutaneous tumours and
495% of those from intraperitoneal tumours. Enrichment of
hFL-HCCs to Z95% was achieved by negative sorting using
magnetic bead immune selection to eliminate murine cells
(positive for H-2 Kd; Fig. 1e). Tumours contained, on average,
B8 106 hFL-HCC cells g 1 of tumour.
RNA-seq identifies DNAJB1-PRKACA chimera in the tumor
line. A signature feature of most primary hFL-HCCs is the
expression of a fusion transcript, DNAJB1-PRKACA18,19, which
was shown recently in a study of 78 primary tumours to be
present in at least B80% of FL-HCCs20. To determine whether
the tumour line has this marker, we performed transcriptomic
analysis. Specifically, we carried out paired-end high-throughput
RNA sequencing in four different hFL-HCC passages of the
transplantable tumour line, as well as in purified populations of
human adult hepatocytes (hAHEPs) from three different donors.
We obtained an average of B150 million paired-end reads per
sample, of which an average of B83% mapped uniquely to the
Table 1 | Limiting dilution tumourigenicity assays of hFL-HCC cells in NSG mice.
Tumour cells injected Passage # # of cells injected # mice with tumours/
# mice injected
3 months Z4–5 months
Cell suspension comprised of a mixture of host (murine) and human FL-HCC cells P1* 2 107 0/1 1/1 (46 months)
P2 B3 107 2/2 2/2
P3 B3 107 7/9 9/9
P4 B3 107 6/12 12/12
P5 B3 107 4/9 9/9
P6 B3 107 3/20 19/20
P7 B3 107 12/41 41/41
Human FL-HCC cells depleted of host (murine) cells P8 1 105 5/5 5/5
P8 1 104 4/5 5/5
P8 1 103 2/5 5/5
P8 1 102 0/3 3/3
FL-HCC, fibrolamellar hepatocellular carcinomas; HGF, hepatocyte growth factor; KM, Kubota’s medium; VEGF, vascular endothelial cell growth factor.
*P1 was comprised of donor ascites cells, cultured selected in serum-free KM and then injected. P2–P7 were minced tumours comprised ofB65% host mesenchymal cells and B35% human tumour
cells (the # of cells injected is estimated to be the number of human tumour cells); P8 was done with immunoselected (sorted) human cells depleted of murine mesenchymal cells. In the early passages,
it was found that the length of time needed for tumour formation was reduced significantly, from 4–5 months to 2–3 months, by transplanting the tumour cells with supplements comprised of
hyaluronans, HGF and VEGF; the supplements became part of the standard protocol for the transplantation.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9070
2 NATURE COMMUNICATIONS | 6:8070 | DOI: 10.1038/ncomms9070 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
human genome (Supplementary Table 2). We analysed the
sequencing data using MapSplice2 and detected DNAJB1-
PRKACA with high confidence in all four tumour samples of
the hFL-HCC tumour line, but not in any of the hAHEPs
(Fig. 1f). These results support interpretation of the
transplantable tumour line as a bona fide model of hFL-HCC.
Tumourigenicity assays indicate hFL-HCC is rich in CSCs. Cell
suspensions, depleted of murine cells, were transplanted sub-
cutaneously into NSG mice in limited dilution tumourigenicity
assays in cell numbers from 100 to 106 cells. The mice were
monitored for up to 9 months. Tumours formed within B3
months in all mice transplanted with 105 or more cells; within 5–
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Figure 1 | Establishment of a transplantable hFL-HCC tumour line. (a) Subcutaneous tumour generated in NSG mice. (b) Intraperitoneal transplants
resulting in ascites tumours and tumours on serosal surfaces of abdominal organs. (c) Hematoxylin/eosin stained sections of the original solid, intrahepatic
hFL-HCC tumour. (d) Histology of the centres (1) versus perimeters (2) of the subcutaneous xenografted tumour at low and high magnifications. The scale
bar, 25mm (a,c,d). (e) Flow cytometric characterizations of tumour cell suspensions from subcutaneous xenografted tumours indicated that over 50% of
the cells are host (murine) cells as indicated by expression of H2Kd (in data shown, it is 53.5%). Host mesenchymal cells can be minimized to o5% by
negative sorting for H2Kdþ cells. The extent of host mesenchymal cells is greater when tumours are transplanted intraperitoneally; host cells comprised
495% of the cells (data shown indicates 96.3% were host cells). (f) Sashimi plot of RNA-seq read coverage for fusion gene DNAJB1-PRKACA. The
DNAJB1-PRKACA chimera was detected only in the cells of the hFL-HCC transplantable tumour line and not in normal hAHEPs. Solid peaks depict reads per
kilobase per million reads mapped. Splice/fusion junctions are shown as arcs. The fusion junction joins exon1 of DNAJB1 with the start of exon2 of PRKACA.
This fusion gene has been reported previously in FL-HCCs18–20.
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6 months if transplanted with 103–104 cells; and, surprisingly, just
100 cells gave rise to tumours in all mice within 9 months
(Table 1). Thus, the hFL-HCC tumour line proved functionally
rich in CSCs, albeit slow growing. This caused us to investigate
further the expression of stem/progenitor cell markers in the
tumour line.
Stem/progenitor traits detected in the tumour line by IHC. The
hFL-HCC cells, flow cytometrically gated away from murine cells,
were characterized by multiparametric flow cytometry (Fig. 2a,b).
The majority of cells were positive for LGR5 (68.9%) and CD44
(61.4%); a substantial percentage were positive for CD29 (43.7%),
CD24 (32.9%), CD49f (25.4%), CD13 (12.5%), E-cadherin
(12.0%), c-KIT (12.0%) and oncostatin M receptor-OSMR
(10.7%). A low but reproducible percentage of cells were positive
for NCAM (3.7%), EpCAM (4.3%), CXCR4 (4.8%), CD133
(2.3%), TROP-2 (1.4%) and ICAM1 (0.5%). A small percentage
(1.1%) of LGR5þ cells were positive for EpCAM.
Sections of xenografted hFL-HCC tumours were subjected to
Immunohistochemistry (IHC) assays (Fig. 2c,d, and
Supplementary Fig. 2a), and the findings were comparable to
those from the original tumour cells. The xenografts were positive
for CD68, a known trait of hFL-HCCs21; stem/progenitor
markers (SOX17, SOX9, LGR5, sonic hedgehog (SHH), NCAM
and BMI1); pluripotency genes (NANOG, OCT4, KLF4, SOX2
and SALL4); some hepatic markers (HepPar-1, CK7, CK19 and
CK18); endocrine pancreatic markers (PDX1); and sodium iodide
symporter (NIS). The xenografted tissue was negative or only
weakly positive for EpCAM, and negative for alpha-fetoprotein
and MUC6. Collectively these traits implicate a very primitive
and highly aggressive tumour.
Other markers included matrix components that facilitate cell
survival and growth: E-cadherin; syndecan-1 (HS-PG1); hyalur-
onan receptors (CD44); and vascular cell adhesion molecule-1
(VCAM-1). The cells also strongly expressed multiple genes for
multidrug resistance suggestive of insensitivity to diverse
chemotherapeutic agents. The cells did not express hemopoietic
(CD34 and CD45), stellate (CD146) or endothelial cell antigens
(CD31). Negative controls are shown in Supplementary Fig. 2a.
Stem/progenitor traits also detected in primary hFL-HCCs. To
determine if the stem cell traits of the transplantable tumour are
unique to the tumour line or are evident in primary hFL-HCCs,
we obtained paraffin sections from nine original blocks from the
Department of Pathology at the Memorial Sloan Kettering Cancer
Center (MSKCC) and performed IHC assays (Fig. 3a–c, Table 2
and Supplementary Table 3). All sections assayed were positive
for HepPar-1 and SHH. Positive expression was also observed in
7/9 for SOX9, PDX1 and NIS and 4/9 for BMI1.
Tissue microarrays (TMAs) from 18 primary tumours versus
19 normal livers (Table 2 and Supplementary Fig. 2b–c) were also
obtained from MSKCC and subjected to IHC. Whereas stem/
progenitor traits were not observed in any of the 19 normal livers,
all 18 hFL-HCCs were positive for multiple stem/progenitor cell
markers: SOX9 (12/18), SOX17 (8/18), PDX1 (13/18), OCT4
(7/18), SALL4 (3/6) and SHH (18/18). Thus, the transplantable
hFL-HCC tumour line and the 27 hFL-HCC primary
tumours (9 paraffin sections and 18 TMAs) expressed a wealth
of markers for endodermal stem cell traits and some pluripotency
genes.
Spheroids, indicative of CSCs, formed in serum-free medium.
Spheroid formation required that serum-free KM be used
throughout, including for plating of cells, and was facilitated
further by depletion of host mesenchymal cells from the tumour
cell suspensions. The spheroids formed readily, within hours;
proved able to be passaged for months; and were able to generate
secondary spheroids (Fig. 4a,b). The number of primary and
secondary spheroids was significantly increased when they were
cultured with 1mgml 1 hyaluronans (Supplementary Fig. 3a).
Transmission electron microscopy (TEM) of spheroids (Fig. 4c–f
and Supplementary Fig. 3b–f) revealed tumour cells with
microvilli at their apical poles, indicating ability to polarize. Cells
were rich in rough endoplasmic reticulum and Golgi, with
numerous secretory vesicles containing electron-dense granules
typically associated with neuroendocrine traits (for example,
chromogranin) common to pancreatic tumours. Nuclei contained
dispersed chromatin and large nucleoli, implicating high pro-
duction of secretory proteins. Cells were rich in pleomorphic,
irregularly-shaped, non-lucent mitochondria with irregular
disorganized cristae.
Stem/progenitor traits detected in cultures of hFL-HCC cells.
The original hFL-HCC cells from ascites fluid attached and
formed star-like cells (Fig. 5a) but transitioned rapidly with a
day or two into cells loosely attached and connected to
floating cell chains (catena), with cells bound to each other via
E-cadherin linkages. If plated overnight with 2–5% foetal bovine
serum (FBS) and then switched to serum-free KM (Fig. 5b),
primary cultures of hFL-HCC cells and associated mesenchymal
cells attached to the dishes. Whereas the mesenchymal cells
attached and spread, the colonies of hFL-HCCs had some cells
that attached initially but then transitioned steadily within a week
into aggregates that floated into the medium as spheroids. If
depleted of murine cells (Fig. 5c) and plated in serum-free KM,
hFL-HCC colonies remained attached longer (shown are cultures
up to 2 weeks) expanding to form somewhat three-dimensional
(3D) cells with undulating morphologies. These hFL-HCC cells
stained positive for NANOG, CD44 and LGR5, but not for
EpCAM (Fig. 5c).
Stem/progenitor traits lost in differentiation media. Expansion
of the hFL-HCCs in monolayer (or in spheroids) occurred in
serum-free KM. By contrast, serum-free, hormonally defined
media (HDM), utilized previously for lineage restriction of
hBTSCs to hepatocytes (HDM-H), cholangiocytes (HDM-C) or
pancreatic islets (HDM-P)11, were used to try to differentiate
hFL-HCCs. Cells were monitored for morphological (Fig. 6a) and
Figure 2 | Characterization of a transplantable hFL-HCC tumour line. (a) Representative flow cytometric findings of hFL-HCC cells, gated-mouse-H2Kd-
negative, were done. Antigens expressed by a significant percentage of the cells included CD44 (61.4%); CD49f (25.4%); CD24 (32.9%); CD13 (12.5%);
c-KIT (12.0%); E-cadherin (12.0%); and OSMR (10.7%). Other antigens found routinely but in a smaller percentage of cells included CXCR4 (4.8%);
EpCAM (4.3%); CD133 (2.3%); TROP-2 (1.4%); and ICAM1 (0.5%). (b) Double staining of LGR5 and EpCAM in hFL-HCC cells. LGR5þ cells accounted for
68.9% of the cells in the tumours. Of these, only 1.1% were also EpCAMþ . (c) Immunofluorescence assay on hFL-HCC xenotransplantable tumour
demonstrated strong expression of LGR5 and an absence of EpCAM. (d) IHC assays on the xenotransplantable tumour line. The survey included assays for
endodermal stem/progenitor transcription factors and markers (SOX17, SOX9, CD44, LGR5 and CK19); pluripotency genes (NANOG, OCT4, KLF4, SOX2
and BMI1); hepatic and other markers (HepPar-1, CK18, CK7, SHH and CD68); and pancreatic/endocrine markers (PDX1, NGN3 and NIS), which were
strongly expressed. EpCAM was essentially negative, and alpha-fetoprotein was negative. The scale bar, 25mm (c,d).
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immunocytochemical changes (Fig. 6b) and were assayed by
qRT–PCR for stemness and mature markers (Fig. 6c). Peak levels
of stemness genes occurred in KM, whereas those markers were
significantly suppressed in all three differentiation HDM. In
HDM-C, there was an increase in CFTR mRNA and protein.
CFTR is found in normal hBTSCs but its levels increase during
maturation to cholangiocytes. Higher levels of differentiation
were blocked by hFL-HCCs significant production of matrix-
degrading factors that resulted in rapid dissolution (within hours)
of every matrix substratum tested.
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Cell type of origin for hFL-HCCs revealed by RNA-seq. We
performed paired-end high-throughput RNA sequencing in
purified populations of sequential maturational lineage stages of
human hepatic parenchymal cells: hBTSCs, hepatic stem cells
(hHpSCs) and hepatoblasts (hHBs), each from three different
donors (Fig. 7). We obtained an average ofB215 million paired-
end reads per sample, of which an average of B90% mapped
uniquely to the human genome (Supplementary Table 4). We
then compared the data with what we had already generated for
hAHEPs (n¼ 3) and 4 different passages of the hFL-HCC
transplantable tumour line. Gene expression profiles were
strongly correlated among all samples within each cell type
(average pairwise Pearson’s r2¼ 0.98 for the hFL-HCC prepara-
tions; 0.88 for hHBs and hBTSCs; 0.86 for hAHEPs; and 0.81 for
Human adult liver hFL-HCCa
IHC assays on the section of the original blocks of normal adult liver
IHC assays on the sections of the original blocks of hFL-HCC
BMI1 SOX9 PDX1 SHH HepPar-1
SHH positiveNIS positive
NIS negative
PDX1 positive
PDX1 negative
SOX9 positive
SOX9 negative
BMI1 positive
BMI1 negative HepPar-1 positive
b
c
Figure 3 | IHC assays on clinical samples of primary tumours of hFL-HCCs compared with normal adult livers. (a) Hematoxylin/eosin stained paraffin
sections. (b,c) Representative IHC assays on sections from original blocks of normal adult liver versus primary hFL-HCC tumours. The scale bar, 50 mm (a),
25mm (b,c).
Table 2 | Summary of IHC assays on primary tumour samples.
Original block samples TMA samples
Antigen hFL-HCC Antigen Adult liver hFL-HCC
BMI1 4/9 SOX9 0/19 12/18
SOX9 7/9 SOX17 0/19 8/18
PDX1 7/9 PDX1 0/19 13/18
NIS 7/9 OCT4 0/19 7/18
SHH 9/9 SALL4* 0/13 3/6
HepPar-1 5/6 SHH 0/19 18/18
hFL-HCC, human fibrolamellar hepatocellular carcinomas; SHH, sonic hedgehog; NIS, sodium iodide symporter; TMA, tissue microarray.
*With SALL4 staining, some paraffin sections were lost owing to the buffer conditions used for antigen retrieval.
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hHpSCs). The high correlation among the hFL-HCC samples,
from early passage (in the first year) to late passage
(after 4 years), indicated remarkable stability of gene expression
throughout the years of passaging in mice. Cross-category
comparisons revealed that gene expression profiles of hFL-HCCs
were most strongly correlated with those of hBTSCs (Fig. 7a).
This finding was further supported by results of hierarchical
clustering analyses, showing that hFL-HCCs are more closely
related to hBTSCs than to hHpSCs, hHBs or hAHEPs (Fig. 7b,c
and Supplementary Fig. 4).
We also analysed RNA-seq data from all primary hFL-HCC
tumours in The Cancer Genome Atlas (n¼ 3), as well as
from another primary hFL-HCC described by Xu et al.19
(Supplementary Table 5). We showed that the gene signature of
the primary hFL-HCCs more closely resembles that of the
hFL-HCC tumour model and of hepatobiliary stem cell
populations than that of the more differentiated maturational
lineage stages of hepatic parenchymal cells: hHBs and hAHEPs
(Supplementary Fig. 5a). Furthermore, the genes and the
pathways most significantly altered in the hFL-HCC tumour
line relative to hBTSCs are altered in a similar manner in the
primary hFL-HCC tumours (Supplementary Fig. 5b–c). These
findings further support the stem-cell-rich tumour line as a bona
fide model of hFL-HCCs.
Unique molecular features of the hFL-HCC tumour
line (Fig. 7d) included high expression of AGR2 (ref. 22) and
Spheroid cultures of sorted hFL-HCC cells from xenotransplantable tumor line
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Figure 4 | Spheroid cultures of hFL-HCC cells from transplantable tumour line. Plating and maintaining hFL-HCC tumour cells under serum-free
conditions, and especially after depletion of the murine cells, resulted in spheroid formation. (a) Spheroids formed from freshly isolated hFL-HCC cells
depleted of murine cells (1st or primary spheroids) were sustainable in culture for months and were passagable forming secondary spheroids (2nd spheroids).
(b) The number of spheroids formed from 10,000 seeded cells remained similar in primary and secondary spheroids. Data are represented as the mean
spheroids (4100mm) count±s.d. (triplicate samples). (c–f) TEM of spheroids. (c); tumour cells displayed numerous microvilli at their apical pole and tight
junctions, meaning the tumour cells could still polarize. At their apical pole, tumour cells had numerous secretory vesicles containing electron-dense granules.
Note the presence of microvilli; large numbers of secretory vesicles with electron-dense granules; partially formed ducts (d); nuclei presented dispersed
chromatin and large nucleoli implicating production of secretory proteins (e); a wealth of mitochondria with aberrant cristae (f). The scale bar, 1mm (c–e),
200nm (f).
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PCSK1 (ref. 23), both previously identified as markers of
primary hFL-HCCs; DCLK1 (ref. 24); and KRT20 (ref. 25),
found in endodermal cancers, particularly of intestine;
POU5F1 (also known as OCT4) and KLF4/5, critical regulators
of stemness26; and AHR, shown to trigger malignant
transformation of HpSCs on binding to dioxins and related
agonists27. DCLK1 was recently identified as the only marker
that accurately distinguishes CSCs from intestinal tumours
from normal stem cells24. Similarly, we found that DCLK1 is
highly expressed in the CSC-rich hFL-HCC tumour line and
primary hFL-HCCs, but lowly expressed in all normal hepatic
maturational lineage stages including hBTSCs and hHpSCs.
Finally, it is notable that HDAC9, which has been linked to
tumour suppressive activity through effects on p53 (ref. 28),
Cultures of the cells from original hFL-HCC patient’s ascites fluid
Cultures of unsorted hFL-HCC cells from xenotransplantable tumor line
Cultures of sorted hFL-HCC cells from xenotransplantable tumor line
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Figure 5 | Monolayer cultures of hFL-HCC cells from original ascites fluid and from transplantable tumour line. (a) Suspensions of the original hFL-HCC
cells from patient’s ascites fluid were plated onto culture plastic and in serum-free KM. The cells transiently attached and formed star-like cells.
Subsequently, the cells became loosely attached to the dish but remained attached to each other via E-cadherin linkages such that they formed floating cell
chains (catena). Cells were readily lost with media changes (b) Primary cultures of the transplantable tumour line yielded cells with a similar appearance to
the original ascites cells. (c) Depletion of the host (murine) cells enabled hFL-HCC cells to form colonies at single cell seeding densities and that grew into
colonies within 2 weeks. After 2 weeks, these cells morphologically resembled the cultures of the original ascites cells. The flattened, monolayer cells
expressed pluripotency and stem cell genes (NANOG, CD44 and LGR5) but not EpCAM. The scale bar, 100mm.
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is most highly expressed in hBTSCs but missing altogether in
hFL-HCCs.
Expression data are shown for representative stem/progenitor,
hepatocytic, biliary and pancreatic genes, as well as
components of the hedgehog signalling pathway, and HDAC
genes (Supplementary Fig. 6). Results of pathway enrichment
analysis for genes differentially expressed in hFL-HCCs compared
with hHpSCs or hBTSCs are also shown (Supplementary Fig. 7).
Cultures of sorted hFL-HCC cells from xenotransplantable tumor line in differentiation medium
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Figure 6 | Differentiation assay of FL-HCC cells from transplantable tumour line. (a) Expansion versus differentiation conditions for hFL-HCC cells
resulted in distinct morphologies of the hFL-HCC colonies and changes in their stem cell versus tissue-specific gene expression. Cultures in serum-free KM
retained stemness traits throughout the weeks (to months) of culture. By contrast, cultures in serum-free, HDM tailored for lineage restriction of
stem cells to hepatocytes (HDM-H), cholangiocytes (HDM-C) or pancreatic islets (HDM-P) caused transient distinctions in morphology that transitioned
secondarily towards spheroid formation. (b) During the few days when morphological changes were observed, there was an increase in expression of
CFTR, a trait of maturing or mature cholangiocytes. (c) qRT–PCR assays showed that stem cell traits (NANOG, POU5F1, SOX2, PROM1) were suppressed in
all the HDM. Surprisingly, so were KRT18 and PDX1 and to a lesser extent KRT7. CD44 was partially suppressed in HDM-H and HDM-C but strongly
suppressed by HDM-P; LGR5 was suppressed in HDM-H and HDM-C but not in HDM-P; TACSTD1 (also known as EpCAM), KRT19 and CFTR were
modestly suppressed in HDM-H and HDM-P, but especially CFTR was actually elevated in HDM-C, and TACSTD1 and KRT19 were not affected. Data are
expressed as the mean±s.d. (triplicate samples). Statistically significant (**Po0.01, *Po0.05, by Student’s t-test with comparison to KM as controls).
The scale bar, 100 mm.
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Interestingly, the pathways most significantly altered in
hFL-HCCs relative to hBTSCs are those that govern lipid and
bile acid homoeostasis.
Finally, we detected the DNAJB1-PRKACA chimera in the
hFL-HCC tumour line and in the primary hFL-HCCs but not
in any maturational lineage stage of the normal hepatic
parenchymal cells, confirming that it is uniquely expressed in
hFL-HCCs. Sashimi plots for the fusion transcript are shown
(Fig. 7e).
The hFL-HCC tumour line most closely resembled hBTSCs.
The finding from the transcriptomic profiling that the hFL-HCCs
closely resemble normal hBTSCs caused us to analyse the
hBTSCs in situ and in vitro to learn to what extent there
was overlap between hFL-HCCs and particular hBTSCs sub-
populations (Fig. 8 and Supplementary Fig. 8). A summary of
known phenotypic traits of the hBTSC subpopulations and of the
maturational lineages to which they give rise is given in
Supplementary Fig. 9 and Supplementary Table 6. Thus far,
we have identified three phenotypically distinct hBTSC
subpopulations in situ, of which two have been observed
also in cultures. The distinct hBTSCs are found in peribiliary
glands (PBGs) throughout the biliary tree and with
gradients in their phenotypic traits depending on their location
(Fig. 8a,b)7–9,11,13,14. A primary, radial axis of maturation starts
with primitive stage 1 hBTSCs, located in PBGs near the
fibromuscular layer within the bile duct walls and that
express CD44, the hyaluronan receptor, and also the NIS
(Fig. 8c,d) but not LGR5 or EpCAM. The PBGs at levels
intermediate between the fibromuscular layers and the duct
lumen contain cells expressing LGR5 but not EpCAM
(stage 2 hBTSCs). Those nearest to the lumen (and also in
crypts within gallbladders) express both LGR5 and EpCAM
(stage 3 hBTSCs). Finally, at the duct lumens are found only
cells that express mature markers and are devoid of stem
cell traits.
Two of the three hBTSC subpopulations identified from in situ
studies correlated with particular types of colonies in culture
(Fig. 8e-h). Plating the hBTSCs into serum-free KM and onto
culture plastic or onto hyaluronan substrata resulted in cells
expressing endodermal transcription factors (for example, SOX9,
SOX17 and PDX1), pluripotency genes (for example, OCT4 and
KLF4) and LGR5. These were recognized morphologically as
colonies of undulating, motile cells with irregular processes.
A second category consisted of carpet-like colonies of cuboidal
cells with EpCAM on every cell (Fig. 8g,h). Cells devoid of both
LGR5 and EpCAM were never observed in culture either because
the culture conditions were not adequate or because culturing the
cells activated LGR5 expression. The hFL-HCC tumour line had
minimal expression of EpCAM and therefore was most similar to
the more primitive EpCAM-negative hBTSC subpopulations.
Discussion
Fibrolamellar hepatocellular cancers are devastating tumours for
which the 5-year survival is only 45%; overall mortality is 60%;
and half the patients have metastases at the point of diagnosis1–5.
Also concerning is that they are increasing in frequency from
unrecognized liver cancers in the 1970s to B5% of all liver
cancers today3–5. As yet, there is no explanation for this increase.
Nor is it understood why patients are primarily children to young
adults, and more rarely, middle-aged adults, with no prior history
of liver disease.
The ability to analyse the variables contributing to the
pathogenesis for hFL-HCCs and to search for effective treatments
has been severely restricted by the lack of any model system,
forcing investigators to deal entirely with primary tumour
samples, ones extremely difficult to obtain. Thus, it is of
considerable importance that we have succeeded in establishing
the first-ever PDX (patient -derived xenograft) model of hFL-
HCCs, a transplantable tumour line (not a cell line) that is
maintained in immune-compromised hosts such as NSG mice.
Prior efforts to produce hFL-HCC tumour lines (or cell lines)
have failed. The efforts failed initially with the ascites tumour cells
(those that eventually gave rise to the tumour line) when the cells
were transplanted immediately into immune-compromised host.
Success proved dependent on culture selection in KM, a serum-
free medium designed for endodermal stem/progenitors7,11,15,29,
and on patience to allow the months (more than 6) required for
initial tumour formation. Once established, the hFL-HCC cells
were able to generate tumours in all (100%) of the animals
transplanted. The speed at which the tumours formed was
dictated by the number of cells transplanted and was enhanced by
use of supplements, particularly hyaluronans, HGF and VEGF.
The hFL-HCC tumour cells were highly invasive and
aggressive, albeit slow to form the tumours, since they were able
to penetrate through the body wall accessing the peritoneum;
when transplanted intraperitoneally, they spread onto every
serosal surface. The ability for invasion correlated with the
striking ability of the hFL-HCC tumour cells to dissolve every
extracellular matrix substratum tested in vitro. Other attributes
indicating aggressiveness were the tumour’s desmoplastic
traits30,31 in which host mesenchymal cells comprised B70% of
the subcutaneous tumours and 495% of the intraperitoneal
tumours, levels higher than those reported for HCCs32 or
CCAs33. Immunoselection to remove host cells resulted in
hFL-HCC cells readily cultured as spheroids and with
phenotypic traits consistently expressed even after years of
passaging in NSG mice. Consistent with reports by others,
tumour stroma produced paracrine signals (matrix and soluble
signals), important in tumour progression and metastasis30,34.
IHCs and histology provided evidence for the relationship of
hFL-HCC tumour to endodermal stem/progenitors. Histology
demonstrated the typical bands of stroma1–5 surrounding
clumps of large tumour cells having prominent nuclei4
Figure 7 | Global gene expression by RNA-seq analyses. (a) Correlation heatmap of gene expression profiles from RNA sequencing of hAHEPs, hBTSCs,
hHBs and hHpSCs, each from three different donors, as well as hFL-HCC from four tumours in different passaged lines of the transplantable tumour line.
Tumour cells were depleted of host-murine cells before being analysed by RNA-seq. Values between 0 and 1 shown in each box correspond to the median
pairwise Pearson’s correlation coefficient. All genes with an average normalized expected count 450 across all samples were included in the analyses
(n¼ 14,394). (b,c) Results of hierarchical clustering analysis based on Euclidian distance of gene expression profiles across the different categories of cells
using either the 10,000 most highly expressed genes (b) or the 248 genes significantly differentially expressed between hBTSCs and hHpSCs (c). For both
(b) and (c), only genes with an average normalized expected count450 in at least one cell category were considered. (d) Histograms of representative
genes with distinct expression patterns in hFL-HCCs are shown. (e) Sashimi plot of RNA-seq read coverage for fusion gene DNAJB1-PRKACA. The DNAJB1-
PRKACA chimera was detected only in the cells of the hFL-HCC transplantable tumour line and not in any of the normal cell populations. Solid peaks depict
reads per kilobase per million reads mapped. Splice/fusion junctions are shown as arcs. The fusion junction joins exon1 of DNAJB1 with the start of exon2 of
PRKACA. Four replicate samples of hFL-HCC tumours had 803, 972, 837 and 581 reads, respectively that spanned the fusion junction. We demonstrate that
it is not present in normal hBTSCs, hHpSCs, hHBs or hAHEPs.
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and aberrations in mitochondria35. Co-expression was found for
some stem/progenitor markers (for example, OCT4, KLF4 and
SHH) and endodermal transcription factors (for
example, SOX9 and SOX17), expanding prior findings1,36. The
hFL-HCCs expressed some hepatic traits (for example, HNF4 and
HepPar-1), and the remainder expressed endocrine pancreatic
traits (for example, PDX1 and PCSK1) or both. Almost all
expressed NIS at the protein level, extending prior reports that
NIS is expressed in CCAs37 and is a target of transcriptional
regulation by p53 (ref. 38).
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Figure 8 | Normal hBTSCs. (a) Hematoxylin/eosin stained section of biliary tree demonstrating PBGs found throughout the duct wall (intramural glands).
There are others attached by tethers to the bile duct surface (extramural glands). (b) Sections stained by IHC for EpCAM and SOX17. Those within the duct
wall contain cells of varying phenotypic traits that are found to be in a pattern indicating a radial axis of maturation lineages of the hBTSCs. The most
primitive hBTSCs, are located deep within the walls of the bile ducts and near the fibromuscular layers. These cells do not express LGR5 or EpCAM but do
express pluripotency genes (for example, OCT4, SOX2, KLF4 and NANOG) and endodermal stem cell markers (for example, SOX9, SOX17 and PDX1). As
one moves towards the lumen of the bile duct, the cells gradually lose stem cell traits and acquire mature cell traits. At intermediate stages in this process,
the cells acquire LGR5 (stage 2 hBTSCs) and then EpCAM (stage 3 hBTSCS). At the bile duct lumens, no stem cell traits were found but instead only
markers of mature cells. (c,d) NIS, expressed by the primitive hBTSCs (especially those nearest to the fibromuscular layer) but not by mature cells.
(e,f) cultures showing the undulating morphologies of the EpCAM-negative hBTSCs cells. (g) Comparison of the two stages of hBTSCs found in culture:
those with or without EpCAM expression. (h) Stage 2 hBTSCs versus stage 3 hBTSCs with respect to both EpCAM and LGR5. All cultures of hBTSCs were
achievable by plating onto culture plastic (or onto hyaluronans) and in serum-free KM. The scale bar, 100 mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9070
12 NATURE COMMUNICATIONS | 6:8070 | DOI: 10.1038/ncomms9070 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Given the wealth of stem cell traits in the transplantable tumour
line, we obtained primary tumour samples of hFL-HCCs from
MSKCC to validate the relevance of stemness in this tumour type.
Analyses on 27 primary tumours confirmed the expression of some
pluripotency genes (for example, OCT4 and KLF4) and endo-
dermal stem cell traits (for example, SOX17 and PDX1) paralleling
what was observed with the transplantable tumour line.
A noteworthy feature of the tumour line was its richness in
CSCs (460% CSCs based on flow cytometric analyses of
particular markers (for example, CD44þ cells). This is a unique
finding given that the average percentage of CSCs in HCCs is
B0.5–3% (ref. 32) and that in CCAs is B10–20% (refs 39,40).
The richness of CSCs in hFL-HCCs was demonstrated
functionally by their ability to form tumours in 100% of the
mice with as few as 100 cells and by the ease with which they
formed spheroids in culture, ones that were maintained for
months and were able to be passaged.
Phenotypic properties of hFL-HCCs clinically derive in part
from this richness in CSCs and their presumptive origins from
hBTSCs, precursors to liver and pancreas. These findings
provide clarifications for reports of hFL-HCCs with hepatic,
cholangiocytic, and endocrine markers1,2,19,20 and, in our studies,
intestinal traits. The properties of hFL-HCCs implicate origins
from hBTSCs located in PBGs7,8,11 and in crypts at the base of
villi within gallbladders9. Dramatic evidence of the biliary tree
cells as a reservoir of first responders in liver injury and diseases
was shown recently using a novel marking method established by
Kaneko et al.41. Lineage tracing studies in mammals42,43 and
zebra fish44 indicate that the biliary tree is able to replace the
liver following extreme losses of parenchymal cells. In addition,
there are growing numbers of reports implicating biliary tree
stem/progenitors in liver and pancreatic organogenesis7,8,11. The
lineages of stem/progenitors along with adult, diploid
parenchymal cells contribute to liver regeneration through
formation of liver buds that replace damaged parenchymal cells
in diseases such as cirrhosis45.
Early stages of malignant transformation of hBTSCs within
PBGs have been described by Nakanuma and Sato46. More
recently, CSC profiles of HCCs and CCAs have been
characterized extensively by E.G., D.A. and co-workers and
with evidence implicating origins from biliary tree cells for
CCAs40,47. The hFL-HCC tumour line shares properties more
with those of CCAs than HCCs.
The TEM studies on the spheroids revealed many noteworthy
features, but perhaps the most striking were the electron-dense
granules and the extraordinary numbers of mitochondria with
abnormal cristae, a condition typical of certain cancers and
referred to as oncogenic48. This suggests that the mitochondria
generated ATP by oxidative phosphorylation and made the cells
tolerant of hypoxia. An oncocytic condition with such
pleomorphic mitochondria is not known to be associated with
HCCs but has been described in pancreatic cancers49. The
secretory granules are hypothesized to contain factors responsible
for the ability of hFL-HCCs to dissolve rapidly (in a few hours)
every type of matrix tested as substratum.
The strongest evidence of hBTSCs as the likely origins of
hFL-HCCs derives from our RNA-seq studies, which includes
analyses of genes across successive maturational lineage stages
of normal hepatic cells from hBTSCs to hHpSCs to hHBs to
adult hepatocytes (AHEPs). The global transcriptome-wide
analyses indicate that hFL-HCCs more closely resemble hBTSCs
than the other lineage stages analysed. Also, through RNA-seq
analyses we provide independent confirmation that hFL-HCCs
uniquely express the DNAJB1-PRKACA chimera, a fusion gene
coupling the catalytic site of protein kinase A and a heat shock
protein18–20, resulting in stable activation of protein kinase A.
Future investigations are required to explore further this fusion
gene and its potential for diagnostic and/or therapeutic utility. To
our knowledge, this is the first study to perform global
comparative gene expression analysis across four different and
successive maturational lineage stages of the normal human
biliary tree and hepatic parenchymal cells, including multiple,
sequential stages of stem/progenitor cell populations: hBTSCs,
hHpSCs and hHBs.
Genetic analyses of hFL-HCCs have been done by
Zucman-Rossi and co-workers50,51, Torbenson et al.2,35,52,
Honeyman et al.18, Malouf et al.23, Xu et al.19 and, most
recently, Lovet and co-workers20. They have identified additional
biomarkers53,54, including CD68 (ref. 21), which are distinct from
those in other liver cancers32,40. Earlier studies also indicated that
hFL-HCCs have Mosaic G-protein alpha-subunit (GNAS)-
activating mutations, characterized by STAT3 activation55,
epidermal growth factor receptor levels higher than in other
types of hepatic tumours, and no K-RAS mutations53.
The resistance of hFL-HCCs to chemotherapies is probable,
given the cells’ strong expression of multidrug resistance
genes. Their renowned aggressiveness in patients and in
immune-compromised hosts correlates with expression of
multiple genes, including adhesion molecules (E-cadherin,
VCAM-1), matrix receptors (CD44), syndecan-1 (HS-PG) and
matrix-degrading factors that include heparanase. Heparanase
has been shown to fragment the glycosaminoglycan chains,
chemical scaffolds for growth factors and cytokines (for example,
FGFs and VEGFs) releasing glycosaminoglycan/growth factor
complexes as potent mitogens both at the plasma membrane
surface and through processes that transport them to the
nucleus56–58.
The expression of NIS in most hFL-HCCs suggests that
NIS-mediated radio-iodide therapy might be used to treat this
malignancy the way it has been—with great success—in treatment
of thyroid cancer59. However, further studies are ongoing to
confirm that NIS expression correlates with functionality and,
most importantly, that the anion being transported is, in fact,
iodide.
Our findings of remarkably high levels of AHR receptors in
hFL-HCCs and in hBTSCs, and a prior report that dioxins
preferentially affect hHpSCs27, provides clues about possible
aetiological factors of hFL-HCCs. AHR agonists have emerged as
environmental factors from the plastic industries since World
War II, correlating with increased incidence of hFL-HCCs.
Further studies are needed to assess this hypothesis.
There is accumulating evidence that there is dysregulation of
epigenetic modifications in cancers. This guided us in looking
for gene expression of members of the HDAC60,61 and hedgehog
families62,63. An intriguing finding is the complete loss of
HDAC9 in the hFL-HCC tumour line; the relevance of this to
the pathogenic properties of hFL-HCCs is not yet understood.
One possibility is that high expression levels of HDAC9 might
be required in normal stem cells, and loss of HDAC9 might be
associated with altered chromatin structure and pathogenesis of
hFL-HCCs, possibilities that might suggest novel candidate
therapies.
In summary, the hFL-HCCs’ richness in CSCs; their probable
origins from hBTSCs; the hints that AHR agonists might be
aetiological factors; and this first-ever established transplantable
tumour line offer novel diagnostic and therapeutic opportunities
much-needed for this devastating cancer.
Methods
Sourcing of primary tumour samples. Sections (5mm) prepared from the paraffin
blocks of nine primary hFL-HCC tumours and ones from TMAs of 19 normal
adult livers and 18 hFL-HCC patients were obtained from MSKCC and used
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for IHC assays. They were obtained with approval of the Institutional Review
Board at MSKCC. Handling of all the samples fully met compliance and privacy
requirements as per Health Insurance Portability and Accountability Act (HIPAA).
Sourcing of normal tissue. Adult, normal, human biliary tissues were dissected
from tissue connected to intact livers and pancreases obtained but not used for
transplantation into a patient. They were obtained through organ donation
programs via United Network for Organ Sharing. Those used for these studies
were considered normal with no evidence of disease processes. Informed consent
was obtained from next of kin for use of the tissues for research purposes, protocols
received Institutional Review Board approval, and processing was compliant with
Good Manufacturing Practice. The research protocol was reviewed and approved
by the Institutional Review Board for Human Research Studies at the UNC at
Chapel Hill, NC, USA.
Animals. In preliminary studies, several types of immunocompromised mice
(for example, athymic nudes, SCID/NODs, NSGs, both male and female and all of
them 4–6 weeks of age) were obtained from suppliers or were obtained from
breeding colonies on the UNC campus and used as hosts for the hFL-HCC cells.
Although tumours developed in all the different immunocompromised mouse
strains, the findings were most successful with NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ.
These are known commonly as NSGs. These mice are devoid of T or B cells, lack
functional NK cells and are deficient in cytokine signalling. The strain combines
the features of the NOD/ShiLtJ (Stock Number 001976) background, the severe
combined immune deficiency mutation (SCID, which is caused by a spontaneous
mutation in the Prkdc gene), and the IL2 receptor gamma chain deficiency.
The animals were maintained in the quarters maintained by the Division of
Laboratory Animals. Procedures were performed according to protocols approved
by the UNC School of Medicine at Chapel Hill Institutional Animal Care and Use
Committee. All species were inbred and housed in UNC’s Division of Laboratory
Animals sterile facility in micro-isolated autoclaved cages with free access to
autoclaved water and radiation sterilized food.
Original handling of the hFL-HCCs used for the tumour line. The tumour used
to establish the transplantable tumour line was received as ascites fluid replete with
tumour cells. Four litres of ascites fluid were received at UNC within 10 h of
removal from the patient. The cells were centrifuged and pooled, yielding
B2 107 cells. They were plated onto plastic or other substrata (laminin,
hyaluronans, types I, III or IV collagens) in serum-free KM prepared in either
RPMI 1640 or in DMEM-F12 (refs 15,64) and cultured as two-dimensional
monolayers or 3D hydrogels. Serum-free KM has been found to be selective for
endodermal stem cells and progenitors7,11,29 and is not permissive for mature cells.
Culture selection for tumour cells with stem cell properties in monolayer (two-
dimensional) cultures did best on plastic and in KM in DMEM-F12; those in 3D
hydrogels behaved similarly in KM prepared in either DMEM-F12 or RPMI 1640,
grew more slowly, and, in parallel, caused dissolution of hydrogels by hFL-HCC’s
enzyme secretions. The culture selection process proved critical for establishment
of the transplantable tumour line as clarified in further details below.
Transplantation of the hFL-HCC cells. Efforts to establish a tumour line by
transplanting the original ascites tumour cells immediately after removal from the
patient were not successful. Rather, success was achieved only with cells that survived
in serum-free KM and on culture plastic or on/in hyaluronans. The original tumour
sample consisted of 4 l of ascites tumour cells that were centrifuged, plated onto
culture plastic and in serum-free KM for several weeks. Phase images of the original
cultures are given in Fig. 5a. The culture-selected tumour cells were transplanted and
yielded tumours after an initial passage of more than 6 months in NSG mice.
Thereafter, xenografted tumours were passaged by mincing tumour in KM sup-
plemented with 1% hyaluronans (uncross-linked) and further supplemented with
50ngml 1 each of HGF and VEGF. The tumour mince (B20mg) in the KMþ 1%
hyaluronansþ growth factors was injected subcutaneously into mice. The tumour
mince will form tumours in the absence of hyaluronans and growth factors, but will
do so more slowly and will not yield tumours at all in some mice. Consistent,
reproducible tumour formation occurred with the use of the supplements. If
transplanted intraperitoneally, the tumour spread onto the serosal surfaces
throughout the peritoneum and also onto the liver and pancreas.
In passage 8, the tumour cells were dispersed, and the host mesenchymal cells
depleted by sorting negatively for cells positive for, H-2 Kd. The purified hFL-HCC
cells were transplanted subcutaneously at cell numbers from 102 to 106. At all
concentrations from 105 cells and higher resulted in 100% of the mice forming
tumours by 3 months; at 103–104 cells, all formed tumours within 4–5 months. At
100 cells, one tumour formed at 5 months; one at 6 months; and one by 9 months.
Tissue processing of the hFL-HCC tumours to generate cell suspensions for
ex vivo studies was conducted in RPMI 1640 supplemented with 0.1% bovine
serum albumin (BSA), 1 nM selenium and antibiotics. Enzymatic processing buffer
contained 600Uml 1 type IV collagenase and 0.3mgml 1 deoxyribonuclease at
32 C with frequent agitation for 15–20min. Enriched suspensions were pressed
through a 75 gauge mesh and spun at 1,200 r.p.m. for 5min before
re-suspension. Estimated cell viability by trypan blue exclusion was routinely
495%.
Culture conditions. All media were sterile-filtered (0.22 mm filter) and kept in the
dark at 4 C before use. Hyaluronans were obtained from Glycosan Biosciences
(Salt Lake City, Utah; now part of Biotime, Alameda, CA). Type III and IV
collagens and laminin were obtained from Becton Dickenson (RTP, NC).
Kubota’s medium. KM is a serum-free medium designed originally for rodent
hepatoblasts15 and then found effective also for hHBs and hHpSCs29, for hBTSCs7,
and for pancreatic progenitors11. It consists of any basal medium (here being RPMI
1640) with no copper, low calcium (0.3mM), 10 9M selenium, 0.1% BSA, 4.5mM
nicotinamide, 10 12M zinc sulfate heptahydrate, 10 8M hydrocortisone,
5 mgml 1 transferrin/Fe, 5 mgml 1 insulin, 10mgml 1 high density lipoprotein
and a mixture of purified free fatty acids that are added after binding to purified
human serum albumin. The detailed protocol for the preparation of KM has been
given in a methods review64. KM is now available commercially from
PhoenixSongs BIologicals (Branford, CT).
Hormonally defined media. Supplements can be added to KM to generate a
serum-free HDM that will facilitate differentiation of the normal hHpSCs or
hBTSCs to specific fates7,11,65. These include supplementation with calcium to
achieve at or above 0.6mM concentration, 1 nM tri-iodothyronine (T3), 0.1 nM of
copper, and 20 ngml 1 of basic fibroblast growth factor to generate modified
Kubota’s Medium (MKM). The medium conditions over and above these and
needed to selectively yield hepatocytes (HDM-H) versus cholangiocytes (HDM-C)
versus pancreatic islets (HDM-P) are:
(1) HDM-H: MKM supplemented further with 7 mg l 1 glucagon, 2 g l 1
galactose, 10 ngml 1 epidermal growth factor and 20 ngml 1 HGF.
(2) HDM-C: MKM supplemented further with 20 ngml 1 VEGF 165 and
10 ngml 1 HGF.
(3) HDM-P: The MKM is prepared without glucocorticoids and further
supplemented with 1% B27, 0.1mM ascorbic acid, 0.25 mM cyclopamine,
1 mM retinoic acid, 20 ngml 1 of FGF-7 for 4 days, then changed with one
supplemented with 50 ngml 1 exendin-4 and 20 ngml 1 of HGF for 6
more days of induction.
Magnetic immunoselection of hFL-HCC cells. Human tumour cells were isolated
from xenografted tumour as described previously66 with some modifications.
Negative sorting was done using EasySep magnetic bead immunoselection using
the magnetic cups and beads (StemCell Technologies, Vancouver, Canada) and
according to the manufacturer instructions. Briefly the dissociated cells were
washed in phosphate-buffered saline (PBS) with 3% FBS (staining medium)
were treated with FcR blocking antibody and incubated with cocktail of
biotin-conjugated anti-mouse antibody against lineage cells (1:10 dilution, Miltenyi
Biotech, Auburn, CA) and with biotin-conjugated anti-mouse-MHC class I
(H2Kd (clone SF1-1.1, 1:100 dilution) and CD31 (clone; MEC13.3, 1:100 dilution)
antibodies (BD Biosciences, San Jose, CA) at room temperature for 15min.
Cells were incubated with biotin selection cocktail for 15min, and then
incubated with magnetic nanoparticles at room temperature for 10min. The cups
were magnetized, and cells or clumps of cells bound to the walls of the cup; those
not bound (the human cells) were collected into a separate container. The cells
bound to the cups were the mouse cells that were discarded. The human cells were
suspended in KM and then plated.
The cells were plated onto culture plastic or on or in hyaluronan hydrogels
(some of them supplemented with type III or IV collagen or laminin) and provided
with serum-free KM. For the initial plating, the medium was supplemented with
2–5% FBS (HyClone, Waltham, MA). After a few hours, the medium was changed
to the serum-free version, and this was used for all subsequent medium changes.
For the cultures of xenografted tumours, the human cells were sorted by
immunoselection away from the murine (host) mesenchymal cells and then were
plated in serum-free KM from the outset.
Spheroid formation assays. For spheroid formation assays, 1 104 hFL-HCC
cells, depleted of host mesenchymal cells by magnetic sorting, were seeded into
each well of a six-well plate coated with Ultra-Low Attachment surfaces (Corning,
Lowell, MA) and cultured with serum-free KM in the presence or absence of
1mgml 1 hyaluronans (Sigma, St Louis, MO). For secondary spheroid formation
assays, the primary spheroids were collected and then dissociated with NeuroCult
Chemical Dissociation Kit (StemCell Technologies, Vancouver, BC, Canada). Cell
suspensions were centrifuged at 700 r.p.m. 10min and resuspended with KM. After
2 weeks, the number of spheroids (4100 mm) were counted.
Differentiation assays. For these assays, 1 105 hFL-HCC cells, depleted of host
mesenchymal cells by magnetic sorting, were seeded into each well of a 12-well plate
coated with 5mg cm 2 hyaluronan and cultured with KMþ 2% FBS for overnight.
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After 16–20 h, the cells were incubated for 7 days with either serum-free KM (as the
undifferentiated control) or with serum-free HDM-H, HDM-C or HDM-P. After a
total of 7 days culture, cells were harvested for analyses of gene expression.
Flow cytometric analyses. The dissociated cells were incubated at 4 C for 30min
with fluorescein isothiocyanate-conjugated or biotin-conjugated anti-mouse-MHC
class I (against H2Kd; clone: 34-1-2S) (eBioscience, San Diego, CA) and anti-
human antibodies (see Supplementary Table 7) for cell surface markers. For
biotinylated antibody, allophycocyanin-streptavidin (BD Biosciences, San Jose, CA)
was used for visualization. The cells were washed with staining medium before
analysis. For the intracellular staining of LGR5, the cells were incubated with
antibodies against the cell surface antigens as usual, and then, were fixed with 4%
paraformaldehyde (PFA)/PBS at 4 C for 20min. After washing with staining
medium, the cells were resuspended in permeabilization buffer (PBS with 1% foetal
calf serum, 0.1% sodium azide, and 0.1% saponin) with PE-conjugated anti-LGR5
antibody at 4 C for 30min. Antibodies used are listed in Supplementary Table 7.
The labelled cells were washed with permeabilization buffer, and then analysed by
FACSCalibur (BD Biosciences).
Immunohistochemistry and immunocytochemistry. For immunofluorescent
staining, 5 mm frozen sections or cultured cells were fixed with 4% PFA for 20min
at room temperature, rinsed with PBS, blocking with 10% goat serum in PBS for
2 h, and rinsed. Fixed cells were incubated with primary antibodies at 4 C for
14 h, washed, incubated for 1 h with labelled isotype-specific secondary
antibodies, washed, counterstained with 40,6-diamidino-2-phenylindole for visua-
lization of cell nuclei and viewed using Leica DMIRB inverted microscope (Leica,
Houston, TX) or a Zeiss ApoTome Axiovert 200M (Carl Zeiss, Thornwood, NY).
For immunohistochemistry, the tissues were fixed in 4% PFA overnight and
stored in 70% ethanol. They were embedded in paraffin and cut into 5 mm sections.
After deparaffinization, antigen retrieval was performed with sodium citrate buffer
(pH 6.0) or EDTA buffer (pH 8.0) in a steamer for 20min67. Endogenous
peroxidases were blocked by incubation for 15min in 3% H2O2. After blocking,
primary antibodies reacting against human but not mouse cells and were applied at
4 C overnight. M.O.M immunodetection kit (Vector Laboratories, Burlingame,
CA) was used for detecting primary mouse anti-human antibodies on mouse
xeno-transplanted hFL-HCC tumour to avoid the inability of the anti-mouse
secondary antibody to endogenous mouse immunoglobulins in the tissue.
Sections were incubated for 30min at room temperature with ImmPRESS
peroxidase-micropolymer staining kits and 3,3’-diaminobenzidine substrate
(Vector Laboratories, Burlingame, CA). Sections were lightly counterstained with
hematoxylin. Antibodies used are listed in Supplementary Table 8. Control images
are given in Supplementary Fig. 2a.
IHC analyses for NIS. Preparation of sections was as given above. Antigen
retrieval was performed by incubating with boiling 10mM citrate buffer (pH 6.0)
for 15min. Endogenous peroxidase activity was quenched by incubating with 3%
H2O2 in methanol for 10min. Tissue sections were blocked for 1 h with 5% goat
serum in PBS, (137mM sodium chloride, 2.7mM potassium chloride, 4.3mM
sodium phosphate (dibasic, anhydrous), 1.4mM potassium phosphate (monobasic,
anhydrous), pH 7.4). Slides were incubated for 2 h with (or without, for negative
controls) a, site-directed polyclonal antibody against the carboxy-terminus of
human NIS68. The initial concentration of the antibody was 0.5 mgml 1 and was
diluted in 0.5% BSA in PBS 1:5,000. All slides were incubated for 10min with
anti-rabbit poly-HRP conjugated antibody (SuperPicture, Zymed Laboratories).
Slides were monitored after addition of the chromogen solution until the
peroxidase reaction took place. Tissue sections were counterstained with
hematoxylin, dehydrated, mounted and dried overnight. Immunoreactivity was
analysed by light microscopy.
Transmission electron microscopy. The hFL-HCC spheroids were fixed with 3%
glutaraldehyde in 0.15M sodium phosphate buffer, pH 7.4, for 1 hour at room
temperature and stored at 4 C until processed. Following three rinses with 0.15M
sodium phosphate buffer, pH 7.4, the samples were post-fixed for 1 h with 1%
osmium tetroxide/1.25% potassium ferrocyanide/0.15M sodium phosphate buffer,
pH 7.4, followed by rinses in deionized water. The spheroids were dehydrated using
increasing concentrations of ethanol (30, 50, 75 and 100% for 10min each) and two
changes of propylene oxide (15min each). Following infiltration overnight in a 1:1
mixture of propylene oxide/Polybed 812 epoxy resin (Polysciences, Warrington,
PA) and 24 h in 100% resin for 24 h, the spheroids were embedded in fresh Polybed
812 epoxy resin. The spheroids were sectioned transversely at 70 nm using a
diamond knife and a Leica Ultracut UCT microtome (Leica Microsystems, Wetzlar,
Germany). Ultrathin sections were mounted on 200 mesh copper grids and stained
with 4% aqueous uranyl acetate and Reynolds’ lead citrate. The grids were observed
at 80 kV using a LEO EM910 TEM (Carl Zeiss SMT, LLC). Digital images were
taken using a Gatan Orius SC 1000 CCD Camera with DigitalMicrograph 3.11.0
software (Gatan, Pleasantan, CA).
The qRT–PCR assays. For the quantitative reverse transcription polymerase chain
reaction (qRT–PCR) assays, total RNA was extracted from the cells using RNeasy
Micro Kit or RNeasy Mini Kit (Qiagen GmbH, Valencia, CA). First-strand cDNA
synthesized using the Primescript first-strand cDNA synthesis kit (Takara, Otsu,
Japan) was used as a template for PCR amplification. Quantitative analyses of
mRNA levels were performed using Power SYBR Green PCR Master Mix with
Applied Biosystems 7500 Real-time PCR System (Applied Biosystems, Foster City,
CA). The primers were annealed at 50 C for 2min and 95 C for 10min, followed
by 40 cycles of 95 C (15 s) and 60 C (1min). Expression of glyceraldehyde-3-
phosphate dehydrogenase was used as a control standard. Primer sequences are
listed in Supplementary Table 9.
RNA sequencing and gene expression analysis. RNA was purified using Qiagen
RNeasy Kit from hAHEP, hHBs, hHpSCs, and hBTSCs, each from three different
donors, as well as four passages of the hFL-HCC tumour line from the same donor.
RNA integrity analysis was performed using an Agilent 2000 Bioanalyzer.
The cDNA libraries were generated using the Illumina TruSeq Stranded mRNA
preparation kit and sequenced on the Illumina HiSeq 2500 platform. Two samples
were sequenced per lane, occupying a total of 8 lanes for all of the samples
(one flow cell). Quality control analysis was completed using FastQ. Mapping of
sequence reads to the human genome (hg19) was performed with MapSplice2
using default parameters. Transcript quantification was carried out by RSEM
analysis, and DESeq was used to normalize gene expression and identify
differentially expressed genes. MapSplice2 was also used to detect candidate fusion
transcripts. Fusion calls were based on the depth and complexity of reads spanning
candidate fusion junctions. Gene expression profiles were compared using
Pearson’s correlation analysis and hierarchical clustering was performed in
R. Hierarchical clustering was performed following Variance Stabilizing
Transformation provided in the DESeq package. Pathway enrichment analysis
was performed with the Ingenuity Pathway Analysis software. Differential gene
expression analysis was conducted only on genes with a minimum average
normalized count 450 in at least one category.
Statistical analysis. Statistically significant differences between samples are
calculated by using Student’s two-tailed t-test and results are presented as the
mean±s.d. P values of o0.05 were considered statistically significant.
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